{"schema":"hottub-news/story/v1","story":"st_dn52ddkhl4w7yigtwxua","title":"Novartis licencia medicamento da chinesa Abogen em acordo de até US$ 7,8 bilhões","title_en":"Novartis licenses Chinese Abogen drug in up to $7.8 billion deal","outlets":10,"brief":null,"page":"https://hottub.news/stories/novartis-signs-mrna-deal-for-about-7-8-billion-with-chinas-abogen-ksev-dn52ddkhl4","count":11,"items":[{"id":"n_3nde2eyrd3ph4cx4tllq","seq":1529610,"kind":"article","title":"Health: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen","url":"https://www.gdnonline.com/Details/1408444","published":"2026-10-03T12:24:13Z","seen":"2026-10-03T12:24:13Z","lang":"en","source":{"id":"gdnonline.com","name":"gdnonline.com","domain":"gdnonline.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.5,"category2":"health","sentiment":"positive","tone":0.07999999821186066,"political":0.07999999821186066},{"id":"n_vvlxeixitv342sagtaqq","seq":1521112,"kind":"article","title":"Health: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen","url":"https://www.gdnonline.com/Details/1408444/Novartis-strikes-up-to-$78-billion-mRNA-deal-with-Chinas-Abogen","published":"2026-10-03T11:08:21Z","seen":"2026-10-03T11:08:21Z","lang":"en","source":{"id":"gdnonline.com","name":"gdnonline.com","domain":"gdnonline.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.5,"category2":"health","sentiment":"positive","tone":0.07999999821186066,"political":0.07999999821186066},{"id":"n_oyt2aqw2mwnoxomycjlq","seq":1401224,"kind":"article","title":"Novartis Signs Deal With Abogen For MRNA Therapies","url":"https://www.finanzen.ch/nachrichten/aktien/novartis-signs-deal-with-abogen-for-mrna-therapies-1036594189","published":"2026-10-02T17:40:40Z","seen":"2026-10-02T17:40:40Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"health","category_p":0.41999998688697815,"category2":"economy-business","sentiment":"positive","tone":0.18000000715255737,"political":0.05999999865889549},{"id":"n_kncvk634dwti7j67s3ta","seq":1411860,"kind":"article","title":"Novartis Signs Deal With Abogen For MRNA Therapies","url":"https://www.rttnews.com/3696234/novartis-signs-deal-with-abogen-for-mrna-therapies.aspx","published":"2026-10-02T17:04:00Z","seen":"2026-10-02T18:37:17Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"health","category_p":0.41999998688697815,"category2":"economy-business","sentiment":"positive","tone":0.18000000715255737,"political":0.05999999865889549},{"id":"n_wguc74jjzsyg5dtbt44a","seq":1391105,"kind":"article","title":"Novartis fecha acordo de até US$ 7,75 bi com chinesa Abogen para desenvolver medicamentos","title_en":"Novartis signs up to $7.75 billion agreement with Chinese Abogen to develop medicines","url":"https://redir.folha.com.br/redir/online/emcimadahora/rss091/*https://c-level.folha.uol.com.br/negocios/2026/10/novartis-fecha-acordo-de-ate-us-775-bi-com-chinesa-abogen-para-desenvolver-medicamentos.shtml","summary":"A farmacêutica suíça Novartis fechou um acordo com o laboratório chinês Abogen Biosciences para desenvolver conjuntamente medicamentos de RNA, incluindo um possível novo tratamento para doenças autoimunes, informaram as empresas nesta sexta-feira (2). Leia mais (10/02/2026 - 13h42)","published":"2026-10-02T16:42:00Z","seen":"2026-10-02T16:53:28Z","lang":"pt","country":"BR","source":{"id":"kite-folha-uol-com-br-a7488b","name":"folha.uol.com.br","domain":"feeds.folha.uol.com.br"},"via":"kite-folha-uol-com-br-a7488b","entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.75,"sentiment":"positive","tone":0.38999998569488525,"political":0.09000000357627869},{"id":"n_eg2k4o6iz7igmc5zx6ta","seq":1349770,"kind":"article","title":"Novartis licencia medicamento da chinesa Abogen em acordo de até US$ 7,8 bilhões","title_en":"Novartis licenses Chinese Abogen drug in up to $7.8 billion deal","url":"https://valor.globo.com/empresas/noticia/2026/10/02/novartis-licencia-medicamento-da-chinesa-abogen-em-acordo-de-at-us-78-bilhes.ghtml","summary":"A Novartis fechou um acordo avaliado em até US$ 7,8 bilhões para licenciar um candidato a medicamento da chinesa Abogen Biosciences e obter opções sobre futuras terapias, na mais recente parceria entre uma grande farmacêutica ocidental e uma empresa chinesa emergente. Matéria exclusiva para assinantes. Para ter acesso completo, acesse o link da matéria e faça o seu cadastro.","published":"2026-10-02T12:21:16Z","seen":"2026-10-02T13:17:20Z","lang":"pt","country":"BR","source":{"id":"kite-pox-globo-com-4344ca","name":"pox.globo.com","domain":"pox.globo.com"},"via":"kite-pox-globo-com-4344ca","topics":["valor"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"image":"https://s2-valor.glbimg.com/aDlR4pscGzbqo1pefJeeWDir-j0=/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2025/h/D/xuqQfCSEKoYkkxsTzKDw/432052593.jpg","story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.6899999976158142,"sentiment":"positive","tone":0.25999999046325684,"political":0.10000000149011612},{"id":"n_oxyapy2tuezfoi6ilrwq","seq":1343940,"kind":"article","title":"Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal — Update","url":"https://www.morningstar.com/news/dow-jones/202610022725/novartis-to-license-drug-from-chinas-abogen-in-up-to-78-billion-deal-update","published":"2026-10-02T12:15:00Z","seen":"2026-10-02T12:41:46Z","lang":"en","source":{"id":"morningstar.com","name":"morningstar.com","domain":"morningstar.com","outlet":{"wikidata":"Q1389504","name":"Morningstar, Inc.","type":"other","country":"US","designations":["business","database","pinnacle financial solutions ltd","public company"]}},"via":"gdelt-gkg-english","entities":[{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q29520","name":"China","type":"place"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.7799999713897705,"sentiment":"positive","tone":0.4000000059604645,"political":0.11999999731779099},{"id":"n_ep7cppeck7p3f5xwz54q","seq":1349631,"kind":"article","title":"Novartis, China's Abogen Ink $7.8 Billion Deal For mRNA Therapies","url":"https://www.ndtvprofit.com/business/novartis-chinas-abogen-ink-7-8-billion-deal-for-mrna-therapies-12129641","summary":"Abogen will receive $575 million upfront, with up to $7.2 billion in milestone payments tied to clinical development, approvals and commercial milestones.","published":"2026-10-02T12:02:59Z","seen":"2026-10-02T13:16:47Z","lang":"en","country":"IN","source":{"id":"kite-feedburner-com-fcf7b7","name":"feedburner.com","domain":"feeds.feedburner.com"},"via":"kite-feedburner-com-fcf7b7","topics":["business"],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.6200000047683716,"sentiment":"positive","tone":0.5099999904632568,"political":0.12999999523162842},{"id":"n_524vz5oksd3aevsq2slq","seq":1328066,"kind":"article","title":"Novartis signs mRNA deal for about $7.8 billion with China's Abogen","url":"https://www.ksl.com/article/51631446/novartis-signs-mrna-deal-for-about-78-billion-with-chinas-abogen","published":"2026-10-02T11:15:00Z","seen":"2026-10-02T11:19:26Z","lang":"en","source":{"id":"ksl.com","name":"ksl.com","domain":"ksl.com","outlet":{"wikidata":"Q6337865","name":"KSL-TV","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.6100000143051147,"sentiment":"positive","tone":0.4000000059604645,"political":0.10999999940395355},{"id":"n_jrxestvtulj27mnbygpq","seq":1331186,"kind":"article","title":"Novartis signs $7.8 billion Abogen biotech licensing deal","url":"https://www.cnbc.com/2026/10/02/novartis-abogen-china-biotech-deal.html","published":"2026-10-02T11:13:00Z","seen":"2026-10-02T11:39:19Z","lang":"en","source":{"id":"cnbc.com","name":"cnbc.com","domain":"cnbc.com","outlet":{"wikidata":"Q1023912","name":"CNBC","type":"website","country":"US","designations":["business channel","cable channel","news website","specialty channel"]}},"via":"gdelt-gkg-english","topics":["economy","health","science"],"authors":["Elsa Ohlen"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.75,"sentiment":"positive","tone":0.23999999463558197,"political":0.07000000029802322},{"id":"n_dn52ddkhl4w7yigtwxua","seq":1303040,"kind":"article","title":"Novartis signs mRNA deal for about $7.8 billion with China's Abogen – KSEV Radio","url":"https://ksevradio.com/novartis-signs-mrna-deal-for-about-7-8-billion-with-chinas-abogen","published":"2026-10-02T09:00:00Z","seen":"2026-10-02T09:00:36Z","lang":"en","source":{"id":"ksevradio.com","name":"ksevradio.com","domain":"ksevradio.com","outlet":{"wikidata":"Q6337649","name":"KSEV","type":"broadcaster","country":"US","designations":["radio station"]}},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.6499999761581421,"sentiment":"positive","tone":0.3499999940395355,"political":0.1899999976158142}]}